id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-291137-09a3tblt	Chow, Jonathan H.	Angiotensin II for the Treatment of COVID-19–Related Vasodilatory Shock	2020-04-20		.txt	text/plain	1553	66	39	Coronavirus disease (COVID-19) outbreak Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial Effect of disease severity on survival in patients receiving angiotensin II for vasodilatory shock ATHOS-3) Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II The acute respiratory distress syndrome Angiotensin converting enzyme defects in shock: implications for future therapy Reversal of vasodilatory shock: current perspectives on conventional, rescue, and emerging vasoactive agents for the treatment of shock Renin as a marker of tissue-perfusion and prognosis in critically ill patients Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?	cache/cord-291137-09a3tblt.txt	txt/cord-291137-09a3tblt.txt
